Genes and gene expression products that are differentially regulated in prostate cancer

Abstract

This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The invention further relates to polynucleotides differentially expressed in prostate cancer.

We claim:  
     
         1 . A method of diagnosing cancer, tumor progression, hyperproliferative cell growth or accompanying biological and physical manifestations comprising: 
 (a) providing a polynucleotide probe that comprises a sequence capable of hybridizing to any one of the sequences shown in SEQ ID NO:1-339 or complement thereof;    (b) contacting a biological sample for diagnosis with said probe under hybridizing conditions that permit formation of a duplex; and    (c) determining the presence of said duplex.    
     
     
         2 . The method of  claim 1 , wherein said polynucleotide probe comprises at least eight contiguous nucleotides of any of SEQ ID NO:1-339 or complement thereof.  
     
     
         3 . The method of  claim 2 , wherein said polynucleotide probe comprises 8 contiguous nucleotides of the sequences of the clones selected from the group consisting of SL-5, SL-6, SL-9, SL-11, SL-13, SL-68, SL-69, SL-86, SL-90, SL-10O, SL-107, SL-124, SL-135, SL-139, SL-143, SL-152, SL-153, SL-173, SL-177, SL-195, and SL-197.  
     
     
         4 . A method of diagnosing cancer, tumor progression, or hyper-proliferative cell growth comprising. 
 (a) providing an antibody capable of binding to a polypeptide encoded by any one of SEQ ID NO:1-339 or complement thereof;    (b) contacting a biological sample for diagnosis with said antibody under binding conditions that permit formation of an antibody-polypeptide complex; and    (c) determining the presence of said complex.    
     
     
         5 . The method of  claim 4 , wherein said antibody is capable of binding to a polypeptide comprising at least six contiguous amino acid of a polypeptide encoded by any one of SEQ ID NO:1-339 or complement thereof.  
     
     
         6 . The method of  claim 5 , wherein said polypeptide comprises at least six contiguous amino acids of a polypeptide encoded by any one the sequences of the clones selected from the group consisting of SL-5, SL-6, SL-9, SL-1 1, SL-13, SL-68, SL-69, SL-86, SL-90, SL-100, SL-107, SL-124, SL-135, SL-139, SL-143, SL-152, SL-153, SL-173, SL-177, SL-195, and SL-197.  
     
     
         7 . A diagnostic kit comprising: 
 (a) a diagnostic reagent comprising a polynucleotide probe that comprises a sequence capable of hybridizing to any one of SEQ ID NO:339 or complement thereof when said sequence is present in a test biological sample;    (b) a normal biological sample; and    (c) instructions for detecting differences that exist between the levels of duplexes in said test biological sample as compared to said normal biological sample.    
     
     
         8 . A method of treating a mammal with cancer, tumor progression, hyperproliferative cell growth or accompanying biological and physical manifestations, said method comprising administering to said mammal a composition that comprises a therapeutically effective amount of a polynucleotide comprising a sequence capable of hybridizing under stringent conditions to any one of SEQ ID NO:1-339 or complement thereof.  
     
     
         9 . The method of  claim 8 , wherein said polynucleotide comprises at least eight contiguous nucleotides of any of SEQ ID NO:1-339 or complement thereof.  
     
     
         10 . The method of  claim 9 , wherein said polynucleotide is an antisense construct.  
     
     
         11 . The method of  claim 9 , wherein said polynucleotide is a ribozyme construct.  
     
     
         12 . An isolated polynucleotide selected from the group consisting of 
 (a) a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NO:2, 5, 49, 50, 99, 100, 115, 116, 118, 130, 131, 140, 144, 145, 146, 157, 158, 159, 163, 164, 165, 166, 177, 178, 180, 211, 212, 213, 218, 219, 220, 221, 229, 232, 233, 242, 243, 248, 249, 254, 256, 257, 259, 272, 273, 277, 288, 289, 292, 293, 316, 317, and 330;    (b) a polynucleotide encoding a variant of the polypeptide encoded by (a); and    (c) a polynucleotide encoding a protein expressed by a polynucleotide having the sequence of at least one of sequences of (a).    
     
     
         13 . A vector comprising the polynucleotide of  claim 12 .  
     
     
         14 . A host cell comprising the vector of  claim 13 .  
     
     
         15 . A composition comprising a polypeptide, wherein the polypeptide is selected from the group consisting of: 
 (a) a polypeptide encoded by any one of the polynucleotides of  claim 12 , and    (b) a variant of the polypeptide of (a).